IL15 and urinary bladder cancer: N-803, for example, is an IL-15 agonist developed by ImmunityBio; its combination with BCG has been shown to be effective for patients with BCG-unresponsive bladder cancer; 71% of patients who had failed with previous therapies show a complete response with a median duration of 26.6 months [31].